RxDoctor Payments Data

Walter Martin, MD

Pulmonary Disease · Roseville, CANPI 1174566566

Payments from drug & device makers

$27,350in general payments, 2019–2025

Across 1,208 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Viiv Healthcare Company$3K
  • AstraZeneca$3K
  • GSK$2K
  • AbbVie$1K
  • Merck$1K
  • plus $11K from 52 others

What the payments were for

  • Food & beverage$26,68898%
  • Education$6622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead189$5,612
Viiv Healthcare Company117$2,961
AstraZeneca(2 entities)124$2,610
GSK133$2,471
AbbVie(2 entities)78$1,489
Merck58$1,272
Boehringer Ingelheim48$1,137
Astellas Pharma US Inc35$1,095
United Therapeutics Corporation50$969
Regeneron Healthcare Solutions, Inc.24$623
Insmed, Inc.28$601
Johnson & Johnson(2 entities)45$521
Theratechnologies Inc.9$468
Sanofi15$433
Takeda Pharmaceuticals U.S.A., Inc.17$405
Actelion Pharmaceuticals US, Inc.12$359
Amgen(2 entities)17$338
Baxter Healthcare19$336
Electromed, Inc.26$267
Grifols USA, LLC12$258
Pfizer11$238
EMD Serono, Inc.12$236
Verona Pharma, Inc.10$228
Mayne Pharma Commercial LLC12$198
Harmony Biosciences LLC10$190
Mylan Specialty L.p.11$176
Kerecis Limited2$160
Paratek Pharmaceuticals, Inc.9$157
Janssen Products, LP2$155
Bayer6$120
Philips North America LLC6$120
La Jolla Pharmaceutical Company6$118
Advanced Respiratory, Inc8$111
Shionogi Inc5$105
Mallinckrodt Hospital Products Inc.5$93
Viatris Specialty LLC5$83
Shire North American Group Inc3$60
Sunovion Pharmaceuticals Inc.4$57
Pulmonx Corporation2$49
Inspire Medical Systems, Inc.1$47
Genentech USA, Inc.2$43
Teva Pharmaceuticals USA, Inc.2$39
Melinta Therapeutics, LLC2$37
Circassia Inc.2$35
Avadel CNS Pharmaceuticals, LLC1$27
Monaghan Medical Corporation1$26
Aimmune Therapeutics, Inc.1$25
CSL Behring1$24
Lilly USA, LLC1$23
Vyera Pharmaceuticals, LLC1$23
Biogen1$20
Portola Pharmaceuticals, LLC1$18
Fisher & Paykel Healthcare Inc1$17
Covis Pharma GmbH1$16
Biocryst Pharmaceuticals, Inc.1$15
Advanced Accelerator Applications1$15
Hartmann USA, Inc.1$13
Ferring Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,350 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$105,562
Medicare patients
247
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala110$534,580
DovatoDolutegravir Sodium/Lamivudine134$425,549
JulucaDolutegravir/Rilpivirine35$129,592
TivicayDolutegravir Sodium22$57,508
TriumeqAbacavir/Dolutegravir/Lamivudi14$49,738
DescovyEmtricitabine/Tenofov Alafenam19$40,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,232
Cefepime Hcl31$6,183
Combivent RespimatIpratropium/Albuterol Sulfate12$5,852
Ethambutol Hcl41$3,325
Fluconazole51$3,176
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim99$2,826
Tadalafil11$1,819
Rifampin29$1,565
ValacyclovirValacyclovir Hcl28$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq$2,961$662,387205 claims
GileadBiktarvy, Descovy$5,612$575,508129 claims
GSKTrelegy Ellipta$2,471$10,23212 claims
Boehringer IngelheimCombivent Respimat$1,137$5,85212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →